Q2 2022 was weakest quarter for biotech IPOs in more than 5 years The fight is on: As US pricing reform advances through Congress, pharma gears up for a brawl Amazon Care teaming up with Ginger to add behavioral health services After Roe ruling, Bayer enlists lobbyists to fight for contraceptive access Cue Health plots next at-home tests while still raking in COVID profits for now Band of biotechs cut pipeline prospects to focus cash on priority programs Moderna CEO touts plan for triple combo respiratory shot in 'three to five years': report Abbott's concussion blood test helps predict death, disability after 6 months: study Colorado's new hospital price transparency law adds 'real teeth' to weak federal enforcement, experts say With no-go from FDA, Affimed looks elsewhere for its AML bispecific's first human study Market reaction to Sanofi's upcoming litigation over Zantac is 'overblown,' analysts say SyncThink's brain-testing VR tech goes international with European approval Blue Cross Blue Shield of Michigan taps Maven for new integrated family planning, maternity program Vedanta CEO blames 'challenging environment for biotech' for laying off 20% of staff Featured Story | By Max Bayer Both the number of IPOs and the value of those that did get off the ground were the lowest since at least the first quarter of 2017, a new report says. read more |
| |
|---|
|
Top Stories By Fraiser Kansteiner After the Senate passed a major drug pricing reform Sunday, pharma companies are likely readying their legal slings and arrows. Meanwhile, industry watchers are more divided on the bill’s pros and cons. read more By Heather Landi Amazon Care, which currently offers virtual health visits, in-person primary care visits and prescription delivery, is adding behavioral health care to its slate of services. read more By Zoey Becker Bayer has always been a big player in the contraceptive game, and now it's building its presence in D.C. to lobby for contraceptive access. The company recently brought on new outside lobbyists. read more By Andrea Park Amid somewhat surprising financial results from its portable COVID-19 diagnostic kits during the second quarter of this year, the San Diego-based company is working on quite a queue of future additions to its at-home and point-of-care tests. read more By Nick Paul Taylor Preparing for a prolonged bear market, a raft of biotechs have decided candidates that looked good a few months ago are now an extravagance, leading them to pull back from the programs. Bolt Biotherapeutics, which canned assets to extend its runway into 2025, is joined by ProQR Therapeutics, Harpoon Therapeutics, Kala Pharmaceuticals and Synthetic Biologics in the wave of pipeline cuts. read more By Eric Sagonowsky During the worst of the COVID-19 pandemic, Moderna worked its way into the public consciousness by speeding an effective vaccine through the FDA authorization process. But as demand slows for the first generation of coronavirus vaccines, Moderna is laying plans to build out its portfolio in the years to come. read more By Conor Hale By testing a patient as soon as possible, clinicians may be able to spot proteins from the brain that help paint a more accurate picture of a TBI and its potential for causing long-term complications, comas or death. read more By Dave Muoio Policy experts and transparency advocates say the new law forbidding patient debt collection by noncompliant hospitals could be a roadmap for other states looking to tackle high hospital prices. read more By Annalee Armstrong With a no-go from the FDA, Affimed is redirecting clinical development for an acute myeloid leukemia med outside of the U.S. Affimed filed a new drug application to the U.S. agency in June seeking authorization to begin clinical study for AFM28 here. But the regulatory gatekeeper has said no. read more By Kevin Dunleavy A sudden downturn in the market value of Sanofi—largely fueled by concerns about upcoming multi-district litigation in the United States over heartburn drug Zantac—has some declaring that the sky is falling for the French pharma. But is it really? Analysts from SVB Securities and ODDO BHF believe the market is overreacting to the news. read more By Andrea Park Late last year, the FDA OK’d a system that uses AI and virtual reality technology to assess a patient’s neurological condition—and now that device from SyncThink is heading across the pond, with a newly bestowed CE mark in hand. read more By Paige Minemyer Blue Cross Blue Shield of Michigan will roll out a new family building and maternity support program head of open enrollment. The goal, Blue Cross said, is to address gaps in care and improve outcomes for both parents and babies. read more By James Waldron In a LinkedIn post yesterday evening, Vedanta CEO Bernat Olle said that the company—which is focused on drugs targeting the human microbiome—will be “letting go approximately 20% of our staff. read more Resources Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 